Loading...
XTAECANF
Market cap14mUSD
Dec 24, Last price  
1.90ILS
1D
5.56%
1Q
-29.63%
Jan 2017
-99.58%
IPO
-99.94%
Name

Can Fite Biopharma Ltd

Chart & Performance

D1W1MN
XTAE:CANF chart
P/E
—
P/S
1,969.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-35.74%
Rev. gr., 5y
-27.92%
Revenues
743k
-8.27%
745,210468,99601,785,0000164,717169,500844,7463,820,0002,032,000763,000853,000810,000743,000
Net income
-8m
L-25.42%
00000000-6,571,000-13,052,000-14,806,000-12,595,000-10,236,000-7,634,000
CFO
-8m
L-21.86%
00000000-4,155,000-10,834,000-12,063,000-9,858,000-10,801,000-8,440,000
Earnings
Mar 26, 2025

Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
URL
https://www.canfite.com/
IPO date
Sep 22, 2005
Employees
8
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
743
-8.27%
810
-5.04%
853
11.80%
Cost of revenue
8,938
10,906
13,695
Unusual Expense (Income)
NOPBT
(8,195)
(10,096)
(12,842)
NOPBT Margin
Operating Taxes
63
(20)
Tax Rate
NOPAT
(8,195)
(10,159)
(12,822)
Net income
(7,634)
-25.42%
(10,236)
-18.73%
(12,595)
-14.93%
Dividends
(2,590)
(715)
Dividend yield
1,133.93%
263.83%
Proceeds from repurchase of equity
9,144
20,457
BB yield
-8,253.53%
-7,548.46%
Debt
Debt current
27
48
53
Long-term debt
53
76
195
Deferred revenue
1,713
2,295
3,070
Other long-term liabilities
2,295
3,070
Net debt
(8,842)
(7,855)
(18,891)
Cash flow
Cash from operating activities
(8,440)
(10,801)
(9,858)
CAPEX
(2)
(9)
(11)
Cash from investing activities
498
9,502
(14,511)
Cash from financing activities
9,144
20,457
20,457
FCF
(8,150)
(10,100)
(12,884)
Balance
Cash
8,922
7,979
19,139
Long term investments
Excess cash
8,885
7,938
19,096
Stockholders' equity
(157,354)
(149,720)
(78,893)
Invested Capital
165,350
158,844
99,539
ROIC
ROCE
EV
Common stock shares outstanding
4,261
2,719
1,844
Price
0.03
-69.05%
0.08
-42.86%
0.15
-26.13%
Market cap
111
-51.50%
228
-15.72%
271
13.99%
EV
(8,731)
(7,627)
(18,620)
EBITDA
(8,180)
(10,082)
(12,828)
EV/EBITDA
1.07
0.76
1.45
Interest
14
63
22
Interest/NOPBT